Abrocitinib shows sustained efficacy in treating moderate to severe AD across multiple clinical and patient-reported outcome measures.

Please provide your email address to receive an email when new articles are posted on . Historically, patient-reported outcome measures were primarily used for research. Today, surgeons use ...

Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment. What is the potential impact of these novel treatments on disease progression, mortality, and ...

The pretreatment evaluation of patient-reported, health-related quality of life provides valuable prognostic information on ...

The American Academy of Sleep Medicine has developed and validated a patient-reported outcome tool for use in a clinical setting to monitor treatment response and longitudinal symptom progression in ...

An expert discusses how rilzabrutinib uniquely improves quality-of-life metrics, including fatigue and women’s health domains, which previous immune thrombocytopenia (ITP) therapies failed to address ...

Forbes contributors publish independent expert analyses and insights. Michael L. Millenson writes about healthcare as a skeptical optimist. An unusual study gives a new twist to the idea of ...

The SISAQOL-IMI consortium, co-led by the European Organization for Research and Treatment of Cancer (EORTC) and Boehringer Ingelheim (BI), has published a paper in The Lancet Oncology outlining how ...

Management of Malignant Pleural Effusion in 2024: A Definitive and Unified Global Approach Interestingly, though, the Danish multicenter randomized study 6 did not reproduce the survival benefit ...

Patients with high resiliency may experience better outcomes and faster recovery after ACL reconstruction compared with ...

Patients with previously treated metastatic pancreatic cancer lived roughly twice as long on a daily oral drug called ...